Challenges in developing Geroscience trials
Yves Rolland, Felipe Sierra, Luigi Ferrucci, Nir Barzilai, Rafael de Cabo, Joan B. Mannick, Anthony A. Oliva, William J. Evans, Davide Angioni, Philipe de Souto Barreto, Jérémy Raffin, Bruno Vellas, James L. Kirkland, the G.C.T-TF group, Sandrine Andrieu, Daniel Bacqueville, Heike A. Bischoff‐Ferrari, Guillaume Blivet, Timothy P. Cash, Ana-Maria Cuervo, Noélie Davezac, Andrea Dimet‐Wiley, Alexander Fleming, Friedlander Gérard, Mitzi M. Gonzales, Sophie Guyonnet, Joshua M. Hare, Suzanne Hendrix, Christian Jørgensen, Matt Kaeberlein, Mehmood Khan, Stephen B. Kritchevsky, Aksana Labokha, Olivier Lairez, Stephanie Lederman, Jean Mariani, Lefkos Middleton, John Newman, Angelo Parini, Susan Peschin, Marco Prunotto, Sami Sagol, Suzanne M. Tomlinson, Georg C. Terstappen, Jacques Touchon, Cendrine Tourette, Rob van Maanen, Eric Verdin, Stan Watowich, Lei Zhang, Alex Zhavoronkov
Abstract
Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience.